English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/168872
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia

AuthorsGarcía-Tuñón, Ignacio; Hernández-Sánchez, María; Ordóñez, José Luis ; Alonso-Pérez, Veronica; Álamo-Quijada, Miguel; Guerrero Arroyo, María del Carmen ; Hernández, Jesús M. ; Sánchez-Martín, M.
KeywordsCRISPR/Cas9
Leukemia
Genome edition
BCR/ABL
Issue Date2017
PublisherImpact Journals
CitationOncotarget 8(16): 26027-26040 (2017)
AbstractCRISPR/Cas9 technology was used to abrogate p210 oncoprotein expression in the Boff-p210 cell line, a pro-B line derived from interlukin-3-dependent Baf/3, that shows IL-3-independence arising from the constitutive expression of BCR-ABL p210. Using this approach, pools of Boff-p210-edited cells and single edited cell-derived clones were obtained and functionally studied in vitro. The loss of p210 expression in Boff-p210 cells resulted in the loss of ability to grow in the absence of IL-3, as the Baf/3 parental line, showing significantly increased apoptosis levels. Notably, in a single edited cell-derived clone carrying a frame-shift mutation that prevents p210 oncoprotein expression, the effects were even more drastic, resulting in cell death. These edited cells were injected subcutaneously in immunosuppressed mice and tumor growth was followed for three weeks. BCR/ABL-edited cells developed smaller tumors than those originating from unedited Boff-p210 parental cells. Interestingly, the single edited cell-derived clone was unable to develop tumors, similar to what is observed with the parental Baf/3 cell line. CRISPR/Cas9 genomic editing technology allows the ablation of the BCR/ ABL fusion gene, causing an absence of oncoprotein expression, and blocking its tumorigenic effects in vitro and in the in vivo xenograft model of CML. The future application of this approach in in vivo models of CML will allow us to more accurately assess the value of CRISPR/Cas9 technology as a new therapeutic tool that overcomes resistance to the usual treatments for CML patients.
Publisher version (URL)https://doi.org/10.18632/oncotarget.15215
URIhttp://hdl.handle.net/10261/168872
Identifiersdoi: 10.18632/oncotarget.15215
e-issn: 1949-2553
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
crisprleuk.pdf8,75 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.